Tirzepatide has emerged as a groundbreaking therapy for type 2 diabetes, offering promising results. However, the expense of this innovative drug and Wegovy manufacturer its availability have become key issues for patients and healthcare professionals. While tirzepatide has been approved by regulatory agencies, its costly nature presents a signifi